CN104435927A - 一种治疗心血管狭窄的中药组合物及其制备方法 - Google Patents
一种治疗心血管狭窄的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN104435927A CN104435927A CN201410056410.8A CN201410056410A CN104435927A CN 104435927 A CN104435927 A CN 104435927A CN 201410056410 A CN201410056410 A CN 201410056410A CN 104435927 A CN104435927 A CN 104435927A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- semen
- filtrate
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 27
- 208000031481 Pathologic Constriction Diseases 0.000 title abstract description 9
- 230000036262 stenosis Effects 0.000 title abstract description 9
- 208000037804 stenosis Diseases 0.000 title abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 54
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 239000010135 fructus aurantii immaturus Substances 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 34
- 239000000706 filtrate Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 22
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 19
- 241000221377 Auricularia Species 0.000 claims description 18
- 241000208340 Araliaceae Species 0.000 claims description 16
- 241000218628 Ginkgo Species 0.000 claims description 16
- 235000011201 Ginkgo Nutrition 0.000 claims description 16
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 16
- 239000006187 pill Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 235000011837 pasties Nutrition 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 3
- 238000010266 Sephadex chromatography Methods 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 208000007536 Thrombosis Diseases 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 206010020718 hyperplasia Diseases 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000219925 Oenothera Species 0.000 abstract 1
- 235000004496 Oenothera biennis Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 206010002383 Angina Pectoris Diseases 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 12
- 206010069729 Collateral circulation Diseases 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010040007 Sense of oppression Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000026758 coronary atherosclerosis Diseases 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000003516 pericardium Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004115 mitral valve Anatomy 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000971 adrenergic beta-2 receptor antagonist Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗心血管狭窄的中药组合物,其中,包括按照重量单位配置的如下:决明子20-30g,何首乌20-30g,月见草20-30g,人参15-25g,川芎15-25g,三棱15-25g,桃仁15-25g,黑木耳15-25g,香菇15-25g,银杏叶15-25g,泽兰10-15g,枳实10-15g,五味子10-15g,柏子仁10-15g,丹参15-25g,麦冬10-15g,甘草8-12g。本发明配比简单,使用方便,行气活血,抑制平滑肌细胞的增生;防止血小板聚集,抑制血栓的形成。
Description
技术领域
本发明涉及中药技术领域,特别涉及一种治疗心血管狭窄的中药组合物及其制备方法。
背景技术
心血管狭窄的患者会出现胸闷,气短,心绞痛等症状,心电会有改变,严重还可能会出现心肌缺血。从中医理论上来看,舌脉上观察到以气虚为主,痰瘀征象较轻,冠脉造影显示病人的侧支循环比较丰富,病变血管存在狭窄状况,属中医的“心脉痹阻”。此病发病以老年人为最高,老年之病多为虚,故此病机为本虚标实。虚包括五脏之虚,但以心虚为主要矛盾,心虚必累及阴阳气血,轻则为气虚血虚,重则阴阳气血俱虚,甚则厥脱。实则为“痰”和“瘀”。至于虚与实孰先孰后的问题,一般理论认为先有虚,后才有实。心虚引起气血失畅,气与血,阴阳互根,气为血帅,血为气母,血随气行,迄行则血行,气是主动,血是被动。气虚则生痰,痰湿内停则气机不利,气滞致血瘀,气虚血行乏力,又致血瘀,血瘀可反作用于气,致气滞或气虚进一步加重。
病理学认为:血栓形成和内膜组织的过度增生是引起狭窄的主要原因,因此,抑制血栓的形成和/或组织增生就可以更加有效地防治血管狭窄。鉴于此,用抗凝剂、血小板抑制剂、前列腺素拮抗剂、血脂调节剂、糖皮质激素、血管紧张素转换酶抑制剂和生长抑素类似物等药物预防狭窄,但均末得到满意的结果,因其病根为气滞血瘀。因此,中医认为以益气化痰活血为主的中药是治疗心血管狭窄的原则。心脉痹阻,血液瘀滞是其主要病因。常用的组方如:当归、川芎、赤芍、桃仁、红花、丹参,三七均为活血祛痰之品,温中理气、柴胡疏肝理气,诸药相伍配用,以达活血化瘀、理气通络,共同起到防止再狭窄的作用。根据上述现有技术的背景情况,本发明旨在提供一种配比简单,使用方便,行气活血,抑制平滑肌细胞的增生;防止血小板聚集,抑制血栓的形成的一种治疗心血管狭窄的中药组合物及其制备方法。
发明内容
本发明所要解决的技术问题在于,提供一种配比简单,使用方便,行气活血,抑制平滑肌细胞的增生;防止血小板聚集,抑制血栓的形成的一种治疗心血管狭窄的中药组合物及其制备方法。
为解决上述技术问题,本发明提供了一种治疗心血管狭窄的中药组合物,其中,包括按照重量单位配置的如下:决明子20-30g,何首乌20-30g,月见草20-30g,人参15-25g,川芎15-25g,三棱15-25g,桃仁15-25g,黑木耳15-25g,香菇15-25g,银杏叶15-25g,泽兰10-15g,枳实10-15g,五味子10-15g,柏子仁10-15g,丹参15-25g,麦冬10-15g,甘草8-12g。
或者,包括按照重量单位配置的如下:决明子20-25g,何首乌20-25g,月见草20-25g,人参15-20g,川芎15-20g,三棱15-20g,桃仁15-20g,黑木耳15-20g,香菇15-20g,银杏叶15-20g,泽兰10-12g,枳实10-12g,五味子10-12g,柏子仁10-12g,丹参15-20g,麦冬10-12g,甘草8-10g。
或者,包括按照重量单位配置的如下:决明子25-30g,何首乌25-30g,月见草25-30g,人参20-25g,川芎20-25g,三棱20-25g,桃仁20-25g,黑木耳20-25g,香菇20-25g,银杏叶20-25g,泽兰12-15g,枳实12-15g,五味子12-15g,柏子仁12-15g,丹参20-25g,麦冬12-15g,甘草10-12g。
或者,包括按照重量单位配置的如下:决明子22-28g,何首乌22-28g,月见草22-28g,人参18-22g,川芎18-22g,三棱18-22g,桃仁18-22g,黑木耳18-22g,香菇18-22g,银杏叶18-22g,泽兰11-14g,枳实11-14g,五味子11-14g,柏子仁11-14g,丹参18-22g,麦冬11-14g,甘草9-11g。
治疗心血管狭窄的中药组合物的制备方法,剂型为蜜炼丸剂,其制备方法包括以下步骤:
将所述组份加水浸泡30分钟至1小时,加热煮沸30分钟,过滤,滤液备用;滤渣加水,第二次加热,煮沸30分钟,再过滤,滤液备用;滤渣再加水,第三次加热煮沸40分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,与蜂蜜混在一起搓成细条,制丸腊封包装;
剂型为胶囊剂,其制备方法包括以下步骤:将各组份加重量10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08;所述滤液流经体积为10L的吸附树脂柱,之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到组份药粉,装入胶囊制为胶囊剂;
剂型为片剂,其制备方法包括以下步骤:将各组分切碎加入到多功能提取罐内,加入重量份数比为3000份的水浸泡30~40分钟,煎煮1.5小时后,取出第一次煎煮液备用;药渣加入重量份数比为3000份的水煎煮1小时后,取出第二次煎煮液,将前述两次煎煮液合并过滤,滤液减压浓缩至重量份数比为1000份的溶液,静置沉淀24~36小时,吸取上清液,加热至40~50℃后加入淀粉,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,制片、干燥、成型、分装;
剂型为滴丸剂,其制备方法包括以下步骤:各组分混合并加入其重量之和5-7倍量的水,放入多功能提取罐中,保持气压在0.04-0.06mPa,煎煮2小时;重复上述步骤再次提取1.5小时,提取液过滤100目筛;用吸附树脂精制滤液,用乙醇洗脱;洗脱液减压浓缩至密度1.33-1.35,其中输入空气压力0.04-0.06mPa,真空度为-0.076~-0.088mPa,静置备用;重复前述步骤再次提取1小时;提取液过100目筛;真空浓缩滤液,至生药量1∶1W/V;浓缩液加乙醇沉淀;乙醇沉淀液用100目筛滤过;真空浓缩滤液,进气压力为0.04-0.06mPa,真空度为0.076-0.088mPa;使用葡聚糖凝胶色谱精制,用乙醇洗脱;洗脱液浓缩至密度为1.33-1.35,静置;取上述两种静置液加入聚乙二醇-6000,混合;混合物加热熔融;用滴丸机将混合物制成复方滴丸。
本发明的优点为:破血逐瘀,行气活血,抑制平滑肌细胞的增生;防止血小板聚集,抑制血栓的形成,本发明采用不同药性的中药材,进行了科学配伍,能达到理想的治疗效果,且安全,毒副作用小,使用方便,治愈时间短,治愈后不易复发。能创造较好的社会价值及经济利益。
其主要原理为:何首乌、决明子等可增加肠蠕动,抑制脂肪和胆固醇吸收;月见草促进脂质转运和清除,可升高HDL-C,降低LDL-C。此三味药物为君药,配合使用行气活血,破血逐瘀的如川芎,三菱等药物作为臣药加强药效,同时保持大便通畅,使用如桃仁,柏子仁等,本方中,黑木耳和香菇与破血行气药物共同作为臣药,其中,黑木耳能降血压和防止血管硬化,可缓解冠状动脉粥样硬化。香菇:含有一种核酸类物质,可抑制胆固醇的产生,并可防止动脉硬化和血管变脆,因而香菇对防治心血管疾病有积极作用。其他佐药和使药配合君药、臣药进行配伍,使本发明得到较好的疗效。经60例心血管狭窄患者观察,有效率86.5%,良好率90.8%。
具体实施方式
本发明组方为:决明子20-30g,何首乌20-30g,月见草20-30g,人参15-25g,川芎15-25g,三棱15-25g,桃仁15-25g,黑木耳15-25g,香菇15-25g,银杏叶15-25g,泽兰10-15g,枳实10-15g,五味子10-15g,柏子仁10-15g,丹参15-25g,麦冬10-15g,甘草8-12g。
或者,包括按照重量单位配置的如下:决明子20-25g,何首乌20-25g,月见草20-25g,人参15-20g,川芎15-20g,三棱15-20g,桃仁15-20g,黑木耳15-20g,香菇15-20g,银杏叶15-20g,泽兰10-12g,枳实10-12g,五味子10-12g,柏子仁10-12g,丹参15-20g,麦冬10-12g,甘草8-10g。
或者,包括按照重量单位配置的如下:决明子25-30g,何首乌25-30g,月见草25-30g,人参20-25g,川芎20-25g,三棱20-25g,桃仁20-25g,黑木耳20-25g,香菇20-25g,银杏叶20-25g,泽兰12-15g,枳实12-15g,五味子12-15g,柏子仁12-15g,丹参20-25g,麦冬12-15g,甘草10-12g。
或者,包括按照重量单位配置的如下:决明子22-28g,何首乌22-28g,月见草22-28g,人参18-22g,川芎18-22g,三棱18-22g,桃仁18-22g,黑木耳18-22g,香菇18-22g,银杏叶18-22g,泽兰11-14g,枳实11-14g,五味子11-14g,柏子仁11-14g,丹参18-22g,麦冬11-14g,甘草9-11g。
治疗心血管狭窄的中药组合物的制备方法,剂型为蜜炼丸剂,其制备方法包括以下步骤:
将所述组份加水浸泡30分钟至1小时,加热煮沸30分钟,过滤,滤液备用;滤渣加水,第二次加热,煮沸30分钟,再过滤,滤液备用;滤渣再加水,第三次加热煮沸40分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,与蜂蜜混在一起搓成细条,制丸腊封包装;
剂型为胶囊剂,其制备方法包括以下步骤:将各组份加重量10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08;所述滤液流经体积为10L的吸附树脂柱,之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到组份药粉,装入胶囊制为胶囊剂;
剂型为片剂,其制备方法包括以下步骤:将各组分切碎加入到多功能提取罐内,加入重量份数比为3000份的水浸泡30~40分钟,煎煮1.5小时后,取出第一次煎煮液备用;药渣加入重量份数比为3000份的水煎煮1小时后,取出第二次煎煮液,将前述两次煎煮液合并过滤,滤液减压浓缩至重量份数比为1000份的溶液,静置沉淀24~36小时,吸取上清液,加热至40~50℃后加入淀粉,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,制片、干燥、成型、分装;
剂型为滴丸剂,其制备方法包括以下步骤:各组分混合并加入其重量之和5-7倍量的水,放入多功能提取罐中,保持气压在0.04-0.06mPa,煎煮2小时;重复上述步骤再次提取1.5小时,提取液过滤100目筛;用吸附树脂精制滤液,用乙醇洗脱;洗脱液减压浓缩至密度1.33-1.35,其中输入空气压力0.04-0.06mPa,真空度为-0.076~-0.088mPa,静置备用;重复前述步骤再次提取1小时;提取液过100目筛;真空浓缩滤液,至生药量1∶1W/V;浓缩液加乙醇沉淀;乙醇沉淀液用100目筛滤过;真空浓缩滤液,进气压力为0.04-0.06mPa,真空度为0.076-0.088mPa;使用葡聚糖凝胶色谱精制,用乙醇洗脱;洗脱液浓缩至密度为1.33-1.35,静置;取上述两种静置液加入聚乙二醇-6000,混合;混合物加热熔融;用滴丸机将混合物制成复方滴丸。
本发明的组方可以使用水煎服服用,每日一剂,一日分两次服用,7天为一疗程。
本发明中药制剂药效学研究:
1、心气虚模型小鼠应用本发明中药制剂后,对悬挂引起的紧张有明显抑制作用;使睡眠时间延长;肌张力增加、站立时间延长;采用水迷宫法测得记忆力增加;常压下耐缺氧时间延长;使心气虚小鼠心率恢复;
2、正常小鼠应用本发明中药制剂后,对强迫游泳法和悬挂法引起的紧张有明显的镇静作用;使小鼠的睡眠时间明显延长;对免疫功能明显的提高,使单核吞噬细胞吞噬指数和吞噬活性明显增加,小鼠血清深血素显著升高;
3、对神经内分泌型高血压模型大鼠的高血压有明显的降低作用;心率明显恢复;睡眠时间显著延长,与戊巴比妥钠有明显的协同作用;用水迷宫法试验可见,使模型大鼠的记忆力增加,在迷宫中停留的时间明显缩短;用断头法试验可见,本发明中药组合物使大鼠断头后的张嘴时间明显延长。
急性毒性实验:
本发明中药组合物的小鼠口服最大给药量为210g生药/kg,按公斤体重计算,相当于成人日用量8.8g的1110倍,按体表面积计算,相当于172倍;腹腔给药测得其LD50为41.567生药/kg,其95%可信限为36.124~41.983g生药/kg。说明本发明中药制剂口服毒性低,临床应用较安全。
长期毒性实验:
本发明中药制剂对小鼠按7.81、18.34和40.11g生药/kg连续用药12周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药制剂对大鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药12周及停药3周后,大鼠各脏器均无明显改变。说明本发明中药制剂对大鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
临床实验:
临床资料:心血管狭窄患者60例,均为胸闷,气短,和心绞痛,偶有急性心肌梗死。其中男性34例、女性26例,年龄35~72岁,平均58岁。纳入标准:经冠状动脉造影确诊,年龄35~72岁,性别不限,符合以下条件:①急性心机梗死或稳定型和不稳定型心绞痛;②冠脉造影示2支或2支以上主要冠状动脉75%~99%狭窄或闭塞,至少有1支适合行冠脉支架植入术,并由于各种原因支架植入术后至少还有1支冠脉血管仍存在≥75%以上的狭窄或闭塞;③病变血管直径2.5~4.0mm,且以前未行过经皮冠状动脉腔内成形术(PTCA);④植入冠脉支架为非药物洗脱支架,长度≤25mm;⑤无阿司匹林、肝素、波立维禁忌症。排除标准:①合并糖尿病;②严重心功能不全,心功能IV级;③急性上呼吸道感染;④恶性肿瘤;⑤冠脉病变血管长度>25mm;⑥冠脉分叉病变;⑦已行主动脉2冠状动脉旁路移植术(CABG)。随机将患者分为治疗组30例和对照组30例。
1对比方法:
两组患者根据病情均常规应用调脂药、抗凝剂、血小板受体阻滞剂、硝酸酯类、β2阻滞剂、钙离子阻滞剂、血管紧张素转化酶抑制剂、血管紧张素II受体拮抗剂等作为基础治疗。在支架植入术后24h内,治疗组给予本发明中药胶囊剂每日三次,每次两粒;对照组只采用基础治疗。两组患者的疗程均为6个月。
1.2观察指标及方法
冠脉侧枝积分:采用血管数字减影检测冠脉侧枝循环。冠脉侧枝按照国际Cohen2Rentrop method方法[1]:0=没有任何侧枝血管;1=有侧枝血管被灌注但未到心外膜部分;2=侧枝血管部分灌注到心外膜;3=侧枝血管完全灌注到心外膜。如有多个侧枝则提示有较高的积分;如有数支血管病变存在多处侧枝则选择积分较高的1支血管计算。
射血分数(ejection fraction,EF):运用二维超声心动图机,采用修改Simpson公式测量EF。
统计学处理:应用SPSS11.0统计软件进行方差分析、t检验和χ2检验。
2结果
2.1冠脉侧枝循环积分与ET变化入选时,两组患者均有较少的侧枝循环甚至没有侧枝循环,但治疗组患者经过6个月的治疗,冠脉侧枝循环积分由(0.12±0.10)分提高到(2.05±0.1)分,而且ET也有改善,由(0.46±0.24)提高到(0.51±0.22),而对照组冠脉侧枝循环积分仅由(0.13±0.12)分提高到(1.40±0.11)分,ET治疗前为(0.45±0.21),治疗后为(0.44±0.22);治疗组患者治疗后的冠脉侧枝循环积分较治疗前和对照组均有非常显著性差异(P<0.01),ET有显著性差异(P<0.05);对照组治疗前后的冠脉侧枝循环积分和ET则无显著性差异(P>0.05)。
2.2管腔及支架再狭窄变化 治疗组患者的最小管腔直径和管腔狭窄百分率与对照组比较均无显著性差异(P>0.05),见下表。
两组患者治疗前后管腔狭窄的变化(.x±s)
项目 | 治疗组(n=30) | 对照组(n=30) |
最小管径直径(mm) | ||
血管形成术前 | 1.11±0.43 | 1.13±0.48 |
6个月后 | 1.97±0.74 | 2.08±0.59 |
参考管腔直径(mm) | ||
血管成形术前 | 2.92±0.45 | 2.93±0.46 |
6个月后 | 2.95±0.44 | 2.78±0.42 |
管腔狭窄百分率(%) | ||
血管成形术前 | 61.21±16.00 | 60.59±14.00 |
6个月后 | 3.00±1.00 | 26.00±16.00 |
临床狭窄发生率(%) | 10.00 | 9.68 |
实施例1:
胡某,男,66岁,素有高血压病史,因为心绞痛住院,心绞痛一会儿一阵儿,气短胸闷,心电图检查有心肌缺血。做心脏导管检查,其右冠状动脉拐弯处堵塞了百分之70%。在右降支堵了55%,在回旋支堵65%,在开口处堵了50%。服用如下方剂:
决明子20g,何首乌20g,月见草20g,人参15g,川芎15g,三棱15g,桃仁15g,黑木耳15g,香菇15g,银杏叶15g,泽兰10g,枳实10g,五味子10g,柏子仁10g,丹参15g,麦冬10g,甘草8g。
水煎服服用,每日一剂,一日分两次服用,7天为一疗程。服用6个疗程后,胸闷气短,心绞痛这些症状大幅减轻,心脏导管检查,其右冠状动脉拐弯处堵塞了百分之25%。在右降支堵了20%,在回旋支堵30%,在开口处堵了20%。此比例已经较初次检查时,心血管的狭窄问题被大范围打通,继续服用10个疗程,心电图显示心肌缺血问题基本得到改善。
实施例2:
张某,男,58岁,冠心病病史3年,曾因患急性心肌梗死住院治疗,经溶栓治疗观察,两个月后出院,仍有胸闷、气短、乏力等心肌损伤体征,患者长期卧床,不能下地活动,稍活动后病情加重,心电图提示陈旧性心梗,并严重S-T段改变,心脏超声提示左室舒缩功能严重减退,造影示冠状动脉粥样硬化,导致血管严重狭窄,并应用PTCA后半年发生RS,转中医治疗,停止服用西药,改服根据本发明制备的中药丸剂,使用如下配方:
决明子30g,何首乌30g,月见草30g,人参25g,川芎25g,三棱25g,桃仁25g,黑木耳25g,香菇25g,银杏叶25g,泽兰15g,枳实15g,五味子15g,柏子仁15g,丹参25g,麦冬15g,甘草12g。
每日服用三次,每次四颗,同时加心搏康治疗,50天后病人症状明显好转.经治疗5个月后心电图S-T段改变纠正常,心脏超声示左室收缩功能正常,血小板聚集减少,抑制血栓的形成,减少了对平滑肌细胞的刺激,进一步防止了支架后再狭窄。继续服用40天巩固,停药后至今未复发。
实施例3:
孙某,52岁,女。检查颈部血管。超声所见:右侧颈总动脉:内径7.7mm,内膜增厚,最宽处范围约2.4*0.9mm。vamx:82.9cm/s,RI:0.77。CDFI血流信号充盈良好。左侧颈总动脉:内径7.2mm,内膜增厚,最宽处范围约2.9*1.0mm,左侧颈总动脉分叉处可见数枚强回声斑,较大者约2.0mm,Vamx:56.2cm/s,RI:0.84。CDFI血流信号充盈良好。检查部位:心脏彩色多普勒,室壁运动分析,左心功能测定。心脏:大小:左室44/29mm;右室17/12mm;左室流出道19mm;右室流出道20mm;室壁厚度:左室壁心尖处室壁运动不协调,搏幅:正常;室间隔(T/E)10/8mm;左室后壁(T/E)9/7mm;二尖瓣:纤细,VE:0.35m/s,VA:0.90m/s,EF斜率63mm/s:主动脉瓣;左心功能测定:SV:53ml,EF:61%,FS:32%,HR:76bpm,CO:4.0L/min。二尖瓣可见反流束,反流面积0.9scm。结果:血管严重狭窄,导致心绞痛,心绞痛时轻时重,胸闷气短。使用如下配方:
决明子25g,何首乌25g,月见草25g,人参20g,川芎20g,三棱20g,桃仁20g,黑木耳20g,香菇20g,银杏叶20g,泽兰12g,枳实12g,五味子12g,柏子仁12g,丹参20g,麦冬12g,甘草10g。
水煎服服用,每日一剂,一日分两次服用,7天为一疗程。服用8个疗程后,胸闷气短,心绞痛这些症状大幅减轻,导管检查,血管狭窄问题得到较大改善,继续服用10个疗程后,心绞痛消失,各项指标趋于正常范围值。
实施例4:
王某,男,64岁,有心绞痛,高血压。体征:有发烧症状,体温正常后仍感心悸,脉搏增快,心前区不适,身体疲乏无力。辅助检查:白细胞计数升高,心电图异常,心肌损伤ST-T改变,造影显示冠状动脉粥样硬化,导致血管严重狭窄,并应用PTCA。术后发生RS,对患者停止服用西药,转中医治疗,使用如下配方:
决明子22g,何首乌22g,月见草22g,人参18g,川芎18g,三棱18g,桃仁18g,黑木耳18g,香菇18g,银杏叶18g,泽兰11g,枳实11g,五味子11g,柏子仁11g,丹参18g,麦冬11g,甘草9g。
水煎服服用,每日一剂,一日分两次服用,7天为一疗程。服用10个疗程后,胸闷气短,心绞痛这些症状大幅减轻,导管检查,血管狭窄问题得到较大改善,继续服用15个疗程后,心绞痛消失,各项指标趋于正常范围值。
结果表明:心脉痹阻,血液瘀滞是其主要病因,使用本发明方剂扶正化瘀,故而活血化瘀应是防治狭窄的根本大法。本发明具有扩张血管、降压、改善微循环等功效;兴奋心脏、增强冠脉血流和心肌收缩力的作用,使用本发明方剂能有效防止RS。本发明配比简单,使用方便,行气活血,抑制平滑肌细胞的增生;防止血小板聚集,抑制血栓的形成。
Claims (5)
1.一种治疗心血管狭窄的中药组合物,其特征在于,包括按照重量单位配置的如下:决明子20-30g,何首乌20-30g,月见草20-30g,人参15-25g,川芎15-25g,三棱15-25g,桃仁15-25g,黑木耳15-25g,香菇15-25g,银杏叶15-25g,泽兰10-15g,枳实10-15g,五味子10-15g,柏子仁10-15g,丹参15-25g,麦冬10-15g,甘草8-12g。
2.根据权利要求1所述治疗心血管狭窄的中药组合物,其特征在于,包括按照重量单位配置的如下:决明子20-25g,何首乌20-25g,月见草20-25g,人参15-20g,川芎15-20g,三棱15-20g,桃仁15-20g,黑木耳15-20g,香菇15-20g,银杏叶15-20g,泽兰10-12g,枳实10-12g,五味子10-12g,柏子仁10-12g,丹参15-20g,麦冬10-12g,甘草8-10g。
3.根据权利要求1所述治疗心血管狭窄的中药组合物,其特征在于,包括按照重量单位配置的如下:决明子25-30g,何首乌25-30g,月见草25-30g,人参20-25g,川芎20-25g,三棱20-25g,桃仁20-25g,黑木耳20-25g,香菇20-25g,银杏叶20-25g,泽兰12-15g,枳实12-15g,五味子12-15g,柏子仁12-15g,丹参20-25g,麦冬12-15g,甘草10-12g。
4.根据权利要求1所述治疗心血管狭窄的中药组合物,其特征在于,包括按照重量单位配置的如下:决明子22-28g,何首乌22-28g,月见草22-28g,人参18-22g,川芎18-22g,三棱18-22g,桃仁18-22g,黑木耳18-22g,香菇18-22g,银杏叶18-22g,泽兰11-14g,枳实11-14g,五味子11-14g,柏子仁11-14g,丹参18-22g,麦冬11-14g,甘草9-11g。
5.一种如权利要求1-4任一所述治疗心血管狭窄的中药组合物的制备方法,其特征在于,
剂型为蜜炼丸剂,其制备方法包括以下步骤:
将所述组份加水浸泡30分钟至1小时,加热煮沸30分钟,过滤,滤液备用;滤渣加水,第二次加热,煮沸30分钟,再过滤,滤液备用;滤渣再加水,第三次加热煮沸40分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,与蜂蜜混在一起搓成细条,制丸腊封包装;
剂型为胶囊剂,其制备方法包括以下步骤:将各组份加重量10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08;所述滤液流经体积为10L的吸附树脂柱,之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到组份药粉,装入胶囊制为胶囊剂;
剂型为片剂,其制备方法包括以下步骤:将各组分切碎加入到多功能提取罐内,加入重量份数比为3000份的水浸泡30~40分钟,煎煮1.5小时后,取出第一次煎煮液备用;药渣加入重量份数比为3000份的水煎煮1小时后,取出第二次煎煮液,将前述两次煎煮液合并过滤,滤液减压浓缩至重量份数比为1000份的溶液,静置沉淀24~36小时,吸取上清液,加热至40~50℃后加入淀粉,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,制片、干燥、成型、分装;
剂型为滴丸剂,其制备方法包括以下步骤:各组分混合并加入其重量之和5-7倍量的水,放入多功能提取罐中,保持气压在0.04-0.06mPa,煎煮2小时;重复上述步骤再次提取1.5小时,提取液过滤100目筛;用吸附树脂精制滤液,用乙醇洗脱;洗脱液减压浓缩至密度1.33-1.35,其中输入空气压力0.04-0.06mPa,真空度为-0.076~-0.088mPa,静置备用;重复前述步骤再次提取1小时;提取液过100目筛;真空浓缩滤液,至生药量1∶1W/V;浓缩液加乙醇沉淀;乙醇沉淀液用100目筛滤过;真空浓缩滤液,进气压力为0.04-0.06mPa,真空度为0.076-0.088mPa;使用葡聚糖凝胶色谱精制,用乙醇洗脱;洗脱液浓缩至密度为1.33-1.35,静置;取上述两种静置液加入聚乙二醇-6000,混合;混合物加热熔融;用滴丸机将混合物制成复方滴丸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410056410.8A CN104435927B (zh) | 2014-02-20 | 2014-02-20 | 一种治疗心血管狭窄的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410056410.8A CN104435927B (zh) | 2014-02-20 | 2014-02-20 | 一种治疗心血管狭窄的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104435927A true CN104435927A (zh) | 2015-03-25 |
CN104435927B CN104435927B (zh) | 2017-10-10 |
Family
ID=52883188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410056410.8A Expired - Fee Related CN104435927B (zh) | 2014-02-20 | 2014-02-20 | 一种治疗心血管狭窄的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104435927B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060122214A1 (en) * | 1999-04-22 | 2006-06-08 | Hisashi Kai | Agent for prophylaxis and treatment of angiostenosis |
CN101239151A (zh) * | 2008-03-07 | 2008-08-13 | 谢兴胜 | 一种防治心脑血管疾病的中药及方法 |
CN102836296A (zh) * | 2012-09-18 | 2012-12-26 | 侯增光 | 一种治疗心脑肾为主的血管内皮损伤、狭窄、闭塞的药物 |
-
2014
- 2014-02-20 CN CN201410056410.8A patent/CN104435927B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060122214A1 (en) * | 1999-04-22 | 2006-06-08 | Hisashi Kai | Agent for prophylaxis and treatment of angiostenosis |
CN101239151A (zh) * | 2008-03-07 | 2008-08-13 | 谢兴胜 | 一种防治心脑血管疾病的中药及方法 |
CN102836296A (zh) * | 2012-09-18 | 2012-12-26 | 侯增光 | 一种治疗心脑肾为主的血管内皮损伤、狭窄、闭塞的药物 |
Non-Patent Citations (6)
Title |
---|
励建安: "《康复医学》", 31 July 2008 * |
张鸿修: "《实用冠心病学》", 31 January 2005 * |
李艳艳等: "银杏叶与两种食用菌配伍降血脂作用的实验研究", 《医药前沿》 * |
杨永宗: "《动脉粥样硬化性心血管病基础与临床》", 31 July 2009 * |
沈小珩: "《中医抗衰延寿点津》", 31 May 2005 * |
郑金荣等: "生脉散加味治疗冠心病心绞痛的疗效观察", 《中国基层医药》 * |
Also Published As
Publication number | Publication date |
---|---|
CN104435927B (zh) | 2017-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101524470B (zh) | 一种防治心血管疾病支架再狭窄的中药制剂及制备方法 | |
CN100536900C (zh) | 一种治疗冠心病的中药组合物及其制备方法 | |
CN102526423A (zh) | 一种治疗缺血性心脏病的药物组合 | |
CN108403882A (zh) | 一种治疗冠心病的丹参组合物及其制备方法 | |
CN104586952A (zh) | 岩黄连中药组合物在制备治疗心脏病药物的应用 | |
CN103006831B (zh) | 一种升血小板胶囊中药组合物及其制备方法 | |
CN103933280A (zh) | 一种治疗痰阻心脉型冠心病pci术后心绞痛的中药组合物及其应用 | |
CN1970050B (zh) | 一种治疗心率失常的药物组合物及其制备方法 | |
CN103479763B (zh) | 一种治疗临界高血压的中药组合物及其制备方法 | |
CN104208571A (zh) | 一种治疗心血管狭窄的中药组合物 | |
CN102579804B (zh) | 一种治疗心绞痛的中药 | |
CN103768129B (zh) | 一种预防或治疗高血压的药物组合物 | |
CN104435927B (zh) | 一种治疗心血管狭窄的中药组合物及其制备方法 | |
CN106109951A (zh) | 防治高血糖、高血脂、高血压的药物及其制备方法 | |
CN102204956B (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN104740054A (zh) | 一种防治心肌缺血的药物组合物及其制备方法和用途 | |
CN104547910A (zh) | 黄莪胶囊的药物用途 | |
CN104208438A (zh) | 一种治疗心血管狭窄的中药药物 | |
CN114796420B (zh) | 一种治疗非瓣膜性心房颤动的中药组合物及其中药制剂和应用 | |
CN107913315A (zh) | 一种治疗难治性高血压的中药组合物及其制备方法 | |
CN103055122A (zh) | 预防冠脉支架植入术后再狭窄的药物及其制备方法 | |
CN102397391A (zh) | 治疗高血压、高血脂、高粘血症的药物及其制备方法 | |
CN106728828A (zh) | 一种治疗冠心病的中药制剂及其制备工艺 | |
CN107753738A (zh) | 一种中药组合物在制备治疗肺动脉高压的药物中的应用 | |
CN104940554A (zh) | 一种治疗心脏病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171010 Termination date: 20180220 |